Latest TECN news and sentiment

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently conducting a safety review alongside independent monitoring boards. Following the news, Bristol-Myers Squibb Company (NYSE:BMY) voluntarily paused trials for its competing

Published

9 Sep 2026 22:34

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis AG NVS announced that the late-stage HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) failed to meet the primary endpoint. Del-desiran is an investigational antibody oligonucleotide conjugate (AOC) designed to target the underlying cause of DM1. The global phase III randomized, double-blind, placebo-controlled study, HARMONY, is evaluating the efficacy and safety of del-desiran over 54 weeks in approximately 150 people living with DM1. The stock plunged on the news. This is the second pipeline setback for NVS in the last five days. Last week, N

Published

9 Sep 2026 19:47

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

HIGHCO Aix-en-Provence, 09 September 2026 (6:00 p.m.) HIGHCO: GOOD PERFORMANCE IN H1 2026 (ADJUSTED HEADLINE PBIT UP 25% TO €6.32 M AND ADJUSTED ATTRIBUTABLE NET INCOME UP 29.5% TO €5 M); 2026 GUIDANCE REVISED Increase in business activity in H1 2026 driven by France H1 2026 gross profit of €39.21 m on a reported basis (up 26.7% including Sogec and Budgetbox) and €31.79 m LFL1 (up 2.7%). Organic growth in the Retail Activation division (up 22.3% reported; up 2.5% LFL) driven by good business momentum in France, growth in the Retail Agencies division (up 1.4% reported and LFL) and, as expected,

Published

9 Sep 2026 17:01

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Bristol Myers Squibb BMY announced positive phase II results from the registrational QUINTESSENTIAL study evaluating arlocabtagene autoleucel (arlo-cel; BMS-986393) in heavily pretreated patients with relapsed and refractory multiple myeloma. Arlo-cel is a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CAR T cell therapy. The results are encouraging because arlo-cel targets GPRC5D, giving BMY an opportunity to treat patients already exposed to BCMA-directed therapies. The study met its primary endpoint, demonstrating a statistically si

Published

9 Sep 2026 16:14

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Dyne Therapeutics (DYN) investment thesis remains intact despite a setback for Novartis (NVS) in a p PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

9 Sep 2026 16:10

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded Thermo Fisher(TMO) to Buy from Neutral with a price target of $730, up from $540, after a transfer in analyst coverage. Thermo Fisher is positioned for a durable return to 5%-6%-plus organic growth in 2027, supported by improving pharma/biotech funding, bioprocessing demand, reshoring, AI-driven R&D investment, share

Published

9 Sep 2026 14:51

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

QUALCOMM Incorporated (QCOM) shares rose 3.2% on optimism over its new data center partnership with Amazon Web Services and its AI growth prospects. Roivant Sciences Ltd. (ROIV) shares surged18.8% after positive Phase 2 results for its pulmonary hypertension drug candidate mosliciguat. Bloom Energy Corporation (BE) shares rose 9.6% after the company was added to the S&P 500. Novartis AG (NVS) shares tumbled 13.9% after Phase 3 results showed that its del-desiran drug failed to significantly improve outcomes in patients with myotonic dystrophy type 1. Want the latest recommendations from Zacks

Published

9 Sep 2026 12:15

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Company Logo Opportunities center on earlier genetic diagnosis, targeted FGFR3 therapies, long-acting CNP analogs and oral inhibitors. Developers can improve access, affordability, adherence and lifelong complication management across the US, Europe and Japan. Dublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The achondroplasia market across the seven major markets-the United States, Germany, France, Italy, Spain, the United Kingdom and Japan-was valued at approximately

Published

9 Sep 2026 09:23

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

LONDON, Sept. 9, 2026 /PRNewswire/ -- CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.CD&R Logo Dr. Caforio is currently Chair of the Swiss-headquartered multinational pharmaceutical company Novartis, where he has led the board since 2025. Prior to this, Dr. Caforio spen

Published

9 Sep 2026 09:00

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

8 Sep 2026 20:48

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

2 consolidated

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop. Continue Reading

Published

8 Sep 2026 18:35

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

8 Sep 2026 18:09

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article first appeared on GuruFocus. Novartis (NYSE:NVS), the Swiss pharmaceutical giant, absorbed a brutal setback Tuesday after del-desiran missed the primary endpoint in a pivotal myotonic-dystrophy trial. The stock plunged 10.1% to $138.51, erasing approximately CHF24 billion from the company's market value, according to Reuters. The disappointment strikes directly at Novartis's $12 billion acquisition of Avidity Biosciences. Is NVS fairly valued? Test your thesis with our free DCF calculator.NVS GF Value chart Novartis's HARBOR update showed that the roughly 150-patient study failed

Published

8 Sep 2026 17:59

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector. NVS is headed for its worst single-session performance on record, while Amgen Inc (NASDAQ:AMGN) and NewAmsterdam Pharma Company NV (NASDAQNAMS) are also seeing elevated options activity as traders assess the broader implications of the failed Lp(a) trial. Novartis stock is down 13.4% at $138.63 at last check, after its Phase 3 HORIZON trial evaluating cardiovascular drug pelacarsen failed to meet its primary endpoint.

Published

8 Sep 2026 17:07

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

The European stock markets closed mixed in Tuesday trading amid rising hostilities in the Middle Eas PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Published

8 Sep 2026 16:51

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions. Continue Reading

Published

8 Sep 2026 15:57

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Investing.com -- BMO Capital Markets downgraded Amgen and BioNTech to Market Perform from Outperform on Tuesday, citing limited near-term upside and more balanced risk-reward for biopharma companies. BMO analyst Evan Seigerman cut Amgen's rating while maintaining a price target of $450. Seigerman said commercial execution is now the base case for the stock, with shares up 34% year-to-date, outperforming the broader S&P 500 and the NYSE Arca Pharmaceutical indexes. Amgen continues to face significant loss-of-exclusivity headwinds, Seigerman said, with pressure visible on Prolia/XGEVA, Enbrel, O

Published

8 Sep 2026 12:28

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Monte Rosa Therapeutics, Inc. Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biot

Published

8 Sep 2026 12:00

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in secondary endpoints and exploratory analyses; full HARBOR dataset to be analyzed and appropriate development path to be determined AOC pipeline continues to advance with FDA priority review granted for delpacibart zotadirsen in DMD44 and planned FDA meeting for delpacibart braxlosiran in FSHD, based on positive Phase I/II biomarker data

Published

8 Sep 2026 06:00

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated

This article first appeared on GuruFocus. Amgen (NASDAQ:AMGN), the biotechnology heavyweight behind Repatha and experimental olpasiran, inherited a tougher burden of proof as its shares stood at $437.23. Novartis's pelacarsen successfully lowered lipoprotein(a), or Lp(a), but failed to cut major cardiovascular events in a Phase 3 trial, according to Reuters. That miss sends a blunt warning across the entire Lp(a) drug race: improving the laboratory number may not improve the patient outcome. Warning! GuruFocus has detected 8 Warning Signs with AMGN. Is AMGN fairly valued? Test your thesis with

Published

7 Sep 2026 22:46

Provider record

eodhd

Use in sentiment

Not scored

Reason

Company is not the main subject

Duplicates

1 consolidated